the clinical efficacy of ( d-leu6 ) -des gly-nh2 ( 10 ) -lh x rh ethylamide ( leuprolide ) against prostatic cancer was evaluated at the end of twelve weeks of administration of a daily dose of 20 mg subcutaneous injection to 22 patients with prostatic cancer .
C0023610
lh
C0085272
leuprolide